A Study of a Glaucoma Therapy to Treat Open-Angle Glaucoma or Ocular Hypertension
Launched by ALCON RESEARCH · May 12, 2006
Trial Information
Current as of June 03, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Adults of either sex and any race diagnosed with open-angle glaucoma (with or without pseudoexfoliation or pigment dispersion component)
- Exclusion Criteria:
- • Under 18
About Alcon Research
Alcon Research is a leading global company dedicated to advancing eye care through innovative research and development. As a subsidiary of Novartis, Alcon focuses on the development of cutting-edge products and therapies for vision correction and eye health, including surgical, pharmaceutical, and consumer eye care solutions. With a commitment to enhancing the quality of life for patients worldwide, Alcon Research conducts rigorous clinical trials to evaluate the safety and efficacy of its products, ensuring that they meet the highest standards of care. Through collaboration with healthcare professionals and institutions, Alcon remains at the forefront of ophthalmic advancements, driving progress in the field of vision science.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Fort Worth, Texas, United States
Patients applied
Trial Officials
Julia White
Study Director
Study Director
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials